Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status:
Completed
Trial end date:
2018-06-05
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to demonstrate the efficacy of dupilumab as a
monotherapy in participants ≥12 years to <18 years of age with moderate-to-severe atopic
dermatitis (AD). The secondary objective of the study was to assess the safety of dupilumab
as a monotherapy in participants ≥12 years to <18 years of age with moderate-to-severe AD.